Skip to main content
Insights into Imaging

Table 4 Correlation between gene mutation status and morphological classification of SLADC

From: Solitary lung adenocarcinoma: follow-up CT, pathological-molecular characteristics, and surgical prognosis for different morphological classifications

Classification

Total

EGFR Positive

EGFR Negative

p value

 Type I

   

0.083

  Yes

9

2 (22.2%)

7 (77.8%)

 

  No

27

15 (55.6%)

12 (44.4%)

 

 Type II

   

0.036

  Yes

13

9 (69.2%)

4 (30.8%)

 

  No

23

8 (34.8%)

15 (65.2%)

 

 Type III

   

0.065

  Yes

10

2 (20.0%)

8 (80.0%)

 

  No

26

15 (57.7%)

11 (42.3%)

 

 Type IV

   

0.040

  Yes

4

4 (100%)

0 (0%)

 

  No

32

13 (40.6%)

19 (59.4%)

 

Classification

Total

ALK positive

ALK negative

p value

 Type I

   

0.250

  Yes

7

1 (14.0%)

6 (86.0%)

 

  No

21

0 (0%)

21 (100%)

 

 Type II

   

1.000

  Yes

10

0 (0%)

10 (100%)

 

  No

18

1 (6.0%)

17 (94.0%)

 

 Type III

   

1.000

  Yes

4

0 (0%)

4 (100%)

 

  No

24

1 (4.0)

23 (96.0)

 

 Type IV

   

1.000

  Yes

7

0 (0%)

7 (100%)

 

  No

21

1 (5.0%)

20 (95.0%)

 

Classification

Total

KRAS positive

KRAS negative

p value

 Type I

   

0.141

  Yes

7

0 (0%)

7 (100%)

 

  No

21

7 (33.0%)

14 (67.0%)

 

 Type II

   

0.674

  Yes

10

3 (30.0%)

7 (70.0%)

 

  No

18

4 (22.0%)

14 (78.0%)

 

 Type III

   

0.253

  Yes

4

2 (50.0%)

2 (50.0%)

 

  No

24

5 (21.0%)

19 (79.0%)

 

 Type IV

   

1.000

  Yes

7

2 (29.0%)

5 (71.0%)

 

  No

21

5 (24.0%)

16 (76.0%)

 
  1. SLADC solid lung adenocarcinoma, EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, KRAS Kirsten rat sarcoma viral oncogene
Back to article page